Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement With Giiant Pharma, Inc. For Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
Portfolio Pulse from Happy Mohamed
Palisade Bio, Inc. (NASDAQ:PALI) has entered into an exclusive worldwide licensing agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of Giiant's proprietary targeted prodrug platform for the treatment of inflammatory bowel disease (IBD). The licensed technologies include Giiant's precision delivery technology platform and multiple product candidates, including the lead asset in development, GT-2108. Palisade will pay a portion of the development costs until the first approval of an IND or CTA, and will thereafter assume all development, manufacturing, and commercialization costs.
September 06, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palisade Bio has entered into a licensing agreement with Giiant Pharma, which could potentially expand its product portfolio and increase its market share in the IBD treatment market.
The licensing agreement with Giiant Pharma allows Palisade Bio to develop, manufacture, and commercialize Giiant's proprietary targeted prodrug platform for the treatment of IBD. This could potentially expand Palisade Bio's product portfolio and increase its market share in the IBD treatment market, which represents a multi-billion dollar market opportunity. Therefore, this news is likely to have a positive impact on Palisade Bio's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100